score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5708	643.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	376.0	0.5771	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	MEL-IPI_Pat04-Normal-SM-4NFU6
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat04		
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R138Q	0.7456	114.0	8e-06	0.0																Investigate Actionability	0.0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113	0	49.0	0.2653	1.0	JAK2 p.R138Q (Missense)		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	MEL-IPI_Pat04-Normal-SM-4NFU6
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat04		
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Splice Site	p.R110S	0.1519	316.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0	442.0	0.0928	1.0	JAK1 p.R110S (Splice Site)		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	MEL-IPI_Pat04-Normal-SM-4NFU6
Biologically Relevant				Copy Number	NTRK1	Amplification				0.0	0.0																					0				NTRK1 Amplification		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																					0				ATM Deletion		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																					0				CHEK1 Deletion		MEL-IPI_Pat04	MEL-IPI_Pat04-Tumor-SM-4DJZZ	
Biologically Relevant				Microsatellite Stability	Supporting variants		JAK1 p.R110S (Splice Site), MSH3 p.63_64insAAP (Insertion)																									0				Supporting variants: JAK1 p.R110S (Splice Site), MSH3 p.63_64insAAP (Insertion)		MEL-IPI_Pat04		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.311																									0				COSMIC Signature (version 2) 7 (31%)		MEL-IPI_Pat04		
